MX2020011766A - Metodos de administracion de tratamiento antifibrotico. - Google Patents

Metodos de administracion de tratamiento antifibrotico.

Info

Publication number
MX2020011766A
MX2020011766A MX2020011766A MX2020011766A MX2020011766A MX 2020011766 A MX2020011766 A MX 2020011766A MX 2020011766 A MX2020011766 A MX 2020011766A MX 2020011766 A MX2020011766 A MX 2020011766A MX 2020011766 A MX2020011766 A MX 2020011766A
Authority
MX
Mexico
Prior art keywords
methods
administering anti
fibrotic therapy
disorders
fibrotic
Prior art date
Application number
MX2020011766A
Other languages
English (en)
Inventor
Lin Pan
Jeffrey Mark Harris
Indiana Strombom
Dorothy Sze-Wing Cheung
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2020011766A publication Critical patent/MX2020011766A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación se refiere a métodos de administración del compuesto I para tratar trastornos fibróticos, trastornos inflamatorios o trastornos autoinmunitarios.
MX2020011766A 2016-11-30 2019-05-27 Metodos de administracion de tratamiento antifibrotico. MX2020011766A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662428163P 2016-11-30 2016-11-30
US201662432425P 2016-12-09 2016-12-09

Publications (1)

Publication Number Publication Date
MX2020011766A true MX2020011766A (es) 2020-11-24

Family

ID=60655162

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019006143A MX2019006143A (es) 2016-11-30 2017-11-29 Metodos de administracion de tratamiento antifibrotico.
MX2023003924A MX2023003924A (es) 2016-11-30 2019-05-27 Metodos de administracion de tratamiento antifibrotico.
MX2020011766A MX2020011766A (es) 2016-11-30 2019-05-27 Metodos de administracion de tratamiento antifibrotico.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2019006143A MX2019006143A (es) 2016-11-30 2017-11-29 Metodos de administracion de tratamiento antifibrotico.
MX2023003924A MX2023003924A (es) 2016-11-30 2019-05-27 Metodos de administracion de tratamiento antifibrotico.

Country Status (11)

Country Link
US (3) US11207304B2 (es)
EP (1) EP3548025A1 (es)
JP (3) JP2020502054A (es)
KR (3) KR20190089862A (es)
CN (1) CN110087651A (es)
AU (2) AU2017366881A1 (es)
CA (1) CA3045455A1 (es)
IL (3) IL299447A (es)
MX (3) MX2019006143A (es)
TW (2) TWI826361B (es)
WO (1) WO2018102323A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3045455A1 (en) 2016-11-30 2018-06-07 Genentech, Inc. Methods of administering anti-fibrotic therapy
CN114129517A (zh) * 2020-09-03 2022-03-04 苏州爱科百发生物医药技术有限公司 一种ak3287制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN106459042B (zh) * 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
CA3045455A1 (en) 2016-11-30 2018-06-07 Genentech, Inc. Methods of administering anti-fibrotic therapy

Also Published As

Publication number Publication date
KR20230129628A (ko) 2023-09-08
US20190321344A1 (en) 2019-10-24
CA3045455A1 (en) 2018-06-07
KR20190089862A (ko) 2019-07-31
US20220184046A1 (en) 2022-06-16
JP2022058873A (ja) 2022-04-12
IL299447A (en) 2023-02-01
US11207304B2 (en) 2021-12-28
EP3548025A1 (en) 2019-10-09
JP7495951B2 (ja) 2024-06-05
KR102575344B1 (ko) 2023-09-06
IL289544A (en) 2022-03-01
US11925624B2 (en) 2024-03-12
MX2019006143A (es) 2019-10-17
AU2017366881A1 (en) 2019-05-30
IL289544B2 (en) 2023-06-01
JP2020502054A (ja) 2020-01-23
AU2023263548A1 (en) 2023-11-30
TW201825093A (zh) 2018-07-16
WO2018102323A1 (en) 2018-06-07
KR20220139450A (ko) 2022-10-14
US20240197693A1 (en) 2024-06-20
JP2023139157A (ja) 2023-10-03
MX2023003924A (es) 2023-04-26
CN110087651A (zh) 2019-08-02
IL266480A (en) 2019-07-31
TW202412795A (zh) 2024-04-01
TWI826361B (zh) 2023-12-21

Similar Documents

Publication Publication Date Title
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
TN2017000009A1 (en) Spirocycloheptanes as inhibitors of rock.
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MX2017005457A (es) Metodos y compuestos agonistas de gip.
MX2017010150A (es) Bacterias probioticas recombinantes.
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EA201891251A1 (ru) Бициклические ингибиторы pad4
MY194341A (en) Method of treating a brain tumor
PH12017500933A1 (en) Sublingual administration of riluzole
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
TW201713333A (en) Methods of treating a neurodegenerative disease
PH12017500934A1 (en) Sublingual formulation of riluzole
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
MX2020009709A (es) Composiciones farmaceuticas que comprenden acido dihomo-gamma-linolenico (dgla) y uso de las mismas.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
NZ722600A (en) Methods of treating mild brain injury
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
SG10201804034QA (en) Methods for treating hypotension